Abstract: A method for function call invocation is described. A function call that is implemented in a first programming language and corresponds to a function implemented in a second programming language is received by an application bridge interface implemented in the first programming language. The first programming language is different from the second programming language. A common data structure is generated by a bridge module based at least in part on the function call received by the application bridge interface. The common data structure is sent by the bridge module to a native bridge interface implemented in the second programming language. The common data structure is converted by the native bridge interface to a native data structure implemented in the second programming language. The function is called by the native bridge interface using the native data structure implemented in the second programming language.

Abstract: Stapling assemblies for use with a surgical stapler are provided. In one exemplary embodiment, the stapling assembly includes a cartridge having a plurality of staples disposed therein and a non-fibrous adjunct formed of at least one fused bioabsorbable polymer and configured to be releasably retained on the cartridge. Adjunct systems for use with a surgical stapler are also provided. Surgical end effectors using the stapling assemblies are also provided. Methods for manufacturing stapling assemblies and using the same are also provided.

Abstract: The present disclosure relates generally to disruption of genomic complexes associated with fusion genes via a disrupting agent comprising a targeting moiety and/or an effector, e.g., disrupting, moiety. Described herein are experiments directed at identifying target anchor sequences proximal to fusion genes, e.g., fusion oncogenes; targeting the genomic complexes, e.g., CFLs, comprising said target anchor sequences for disruption (e.g., inhibiting their formation and/or destabilizing them) using disrupting agents; and evaluating the effects of disruption on fusion gene expression and other cell (e.g., cancer cell) characteristics (e.g., growth, viability, etc.).

Abstract: The disclosure relates generally to methods of modifying a nucleic acid sequence, systems for modifying a nucleic acid sequence, and compositions made by said methods or systems.

Abstract: The invention relates generally to uses of tRNA-based effector molecules (TREMs) corresponding to con-rare codons and methods of making the same.

Abstract: A deodorant stick comprising at least 25% by weight liquid triglyceride; a primary antimicrobial having a water solubility of at most about 90 g/L at 25° C.; a fragrance composition comprising at least about 50% natural oils, essential oils, or a combination thereof; and a primary structurant with a melting point of at least 50° C.; said deodorant stick being free of an aluminum salt; and said deodorant stick having a hardness from about 70 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: A novel fuse assembly design utilizes a fuse body, single-piece terminal assembly and a two-piece endbells. The terminal assembly is disposed within the fuse body and includes first and second opposing surfaces with a fuse element extending between a first terminal and a second terminal. The endbell, to be connected to the fuse body, includes first and second endbell portions. Formed within the first endbell portion is a first receptacle and extending from the first endbell portion is a first protrusion. Formed within the second endbell portion is a second receptacle and extending from the second endbell portion is a second protrusion. When the two endbell portions are fastened to one another with the terminal assembly sandwiched between them, the first protrusion engages the second receptacle and the second protrusion engages the first receptacle.

Abstract: Techniques and mechanisms for using passively collected network data to automatically generate a fingerprint prevalence database without the need for endpoint ground truth. The process first clusters all observations with the same fingerprint string and similar source and destination context. The process then annotates each cluster with descriptive information and uses a rule-based system to derive an informative name from that descriptive information, e.g., “winnt amp client” or “cross-platform browser”. Optionally, the learned database may be augmented by a user to clarify custom process labels. Additionally, the generated database may be used to report the inferred processes in the same way as databases generated with endpoint ground truth.

Abstract: An anhydrous stick composition, including deodorant active, an antiperspirant active, or a combination thereof; a carrier; a structurant; and a cyclodextrin perfume complex, comprising cyclodextrin and a perfume, wherein the perfume comprises perfume raw materials and 10% or more, by weight of the perfume, of the perfume raw materials have: a cyclodextrin complex stability constant of about 3.0 or less, a C log P of about 2.5 or less; and a weight average molecular weight of about 200 Daltons or less.

Abstract: Stapling assemblies for use with a surgical stapler are provided. In one exemplary embodiment, the stapling assembly includes a cartridge having a plurality of staples disposed therein and a non-fibrous adjunct formed of at least one fused bioabsorbable polymer and configured to be releasably retained on the cartridge. Adjunct systems for use with a surgical stapler are also provided. Surgical end effectors using the stapling assemblies are also provided. Methods for manufacturing stapling assemblies and using the same are also provided.

Abstract: Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

Abstract: A control path is added to a two-wheeled self-balancing vehicle that has steering augmentation and CMG or reaction wheel actuators for roll balancing. These actuators are used to damp yaw disturbances while preventing roll disturbances, based on a yaw rate disturbance signal received on the control path.

Abstract: An apparatus for controlling a direction and speed of travel an autonomous vehicle or driver assisted autonomous vehicle (AV). A GPS and map module receive a start location and a destination location for the AV. A plurality of sensors identify a current and a proposed lane for the AV. A database of AV baseline maneuver profiles used to control one or more of direction and speed of travel of the AV is provided. A trajectory profile generator module generates a planned path for the AV with lateral acceleration less than 2 Hz, based on the start location, the destination location, the current and proposed lane for the AV, and a selected AV baseline maneuver profile from the database. A steering control module controls the direction of travel of the AV based on the generated AV planned path, and a supervisory control module controls the speed of the AV based on the generated AV planned path and inner ear constraints.

Abstract: In one embodiment, a method for classifying an encrypted flow includes receiving a plurality of packets associated with an encrypted flow traversing a network, collecting telemetry data from the flow without decrypting the flow, sending the telemetry data to a backend system for classification, using the telemetry data to classify the flow using a machine learning classifier, creating a classification response, and using the classification response to modify processing of the flow. In another embodiment, a method for classifying an encrypted flow includes receiving a plurality of packets associated with an encrypted flow traversing a network, collecting telemetry data from the first plurality of packets associated with the flow, sending the telemetry data to a backend system for classification, using the telemetry data to classify the flow using a machine learning classifier, and using the output of the classifier to modify processing of the flow.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: Systems and methods for pacing cardiac conductive tissue are described. An embodiment of a medical system includes an electrostimulation circuit to generate His-bundle pacing (HBP) pulses to stimulate a His bundle, and a cardiac event detector to detect a His-bundle activity within a time window following an atrial activity. The cardiac event detector may use a cross-chamber blanking, or an adjustable His-bundle sensing threshold, to avoid or reduce over-sensing of far-field atrial activity and inappropriate inhibition of HBP therapy. The electrostimulation circuit may deliver HBP in the presence of the His-bundle activity. The system may further recognize the detected His-bundle activity as either a FFPW or a valid inhibitory event, and deliver or withhold HBP therapy based on the recognition of the His-bundle activity.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: An absorbent article comprising a perfume which is suitable for improved release from a cyclodextrin complex, wherein the perfume includes 10% or more, by weight of the perfume, of one or more perfume raw materials having: a cyclodextrin complex stability constant (log k) of less than about 3.0, a ClogP of about 2.5 or less, and a weight average molecular weight of about 200 Daltons or less.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: Disclosed herein are acylated active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.